Led by アルフレッサ ホールディングス, the 4 companies, including MBI, Kidswell and Chiome, executed an agreement to subscribe for the common shares of アルフェナックス バイオロジクス and establish a joint venture. The planned ownership ratios after completion of the subscription and the future business plan are specified.
アルフレッサ ホールディングス, Mycenax Biotech Inc., Kidswell Bio Corporation and Chiome Bioscience Inc. executed an agreement with アルフェナックス バイオロジクス to subscribe for its common shares. アルフェナックス バイオロジクス was established as a wholly owned subsidiary of アルフレッサ ホールディングス and is scheduled to become a joint venture funded by the 4 companies.
Following completion of payment, the expected ownership ratios are アルフレッサ ホールディングス 45%, MBI 45%, Kidswell 7% and Chiome 3%. The joint venture will operate with a biopharmaceutical CDMO business at its core. The site will be located on the business premises of アルフレッサ ファインケミカル株式会社, with the aim of establishing an integrated production system.
This project is being advanced as part of efforts to develop domestic manufacturing facilities for biopharmaceuticals, including biosimilars. アルフェナックス バイオロジクス, the operating entity, was established in 2025, and facility development is currently under way. The companies are targeting the start of commercial production by the fiscal year ending March 2031, with the products, production capacity and timing expected to be specified in the business plan.
The joint venture will integrate MBI's CDMO expertise, アルフレッサ's distribution capabilities, Kidswell's biosimilar development capabilities and Chiome's expertise in antibody drug discovery and CMC development, with the aim of strengthening domestic manufacturing capacity and establishing a stable supply system.